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eply
e welcome the data provided by Dr. Sane, who found telomerase
ctivation in cells from coronary atherectomy specimens (1). It is
orth noting, however, that we assessed telomerase activation
pecifically in neutrophils from atherosclerotic plaques (2). We
ever found telomerase activation in neutrophils from stable
atients, although we found it in about one-third of unstable
atients, particularly in those with a recent episode of rest angina.
hus, our findings suggest that telomerase activation in neutro-
hils may be important in the early phases of coronary instability.
n contrast, Dr. Sane found telomerase activation in about one-
hird of stable patients in cells obtained from coronary atherec-
omy specimens. Interestingly, they found a correlation between
elomerase activation and restenosis rate, suggesting that telomer-
se reactivation in cells, which are not necessarily neutrophils,
ontained in stable atherosclerotic plaque may be important in the
echanism of restenosis. Therefore, the similar prevalence of
elomerase activation in the 2 studies is probably just a coincidence.
evertheless, both studies underscore the biological relevance of
elomerase activation in the microenvironment of the atheroscle-
otic plaque and its different role in different clinical settings. In
ddition, both studies raise a number of unanswered questions.
hy does telomerase activation occur only in a subset of patients?
hat are the molecular pathways leading to telomerase activation?
hat is the relationship between neutrophil telomerase activation
n the plaque and levels of neutrophil activation markers in
eripheral blood? What is the impact of telomerase activation in
he microenvironment of the atherosclerotic plaque on the out-
ome in different clinical settings? Further studies are warranted to
ddress these issues.
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ocal Amyloidosis as a
ossible Component of the Atrial
emodeling Accompanying Trial
n their extensive state-of-the-art paper on the clinical implica-
ions for atrial fibrillation of structural and functional remodeling
f the left atrium, Casaclang-Verzosa et al. (1) do not mention an
mportant structural aspect of the process, namely, intra-atrial
myloid deposition accompanying long-term atrial fibrillation
AF). In the last few years, 2 separate research groups have
rovided evidence that, in humans, longstanding AF is associated
ith intra-atrial deposition of amyloid, particularly in women with
alvular atrial fibrillation (2,3). Amyloid deposits appear to occur
referentially in the left atrium (3). An immunohistochemical
tudy showed that similar deposits were invariably immunoreactive
or atrial natriuretic peptide (ANP) (2). These observations have
rompted the hypothesis that AF-related overproduction of ANP
eads to localized amyloidogenesis and deposition, which in turn
ugments conduction heterogeneity, helping to perpetuate AF
and thereby stimulating further ANP production in a paracrine
oop) (4). In this view, atrial amyloid deposition could be consid-
red to be a further negative consequence of the neurohormonal
isturbances elegantly discussed by the authors of the article. In
ny case, we believe amyloid deposition deserves serious con-
ideration as a potential player in the complex interplay between
natomical and electrical left atrial remodeling, together with
he other pathophysiological changes (stressors) discussed by
he authors, such as interstitial fibrosis, myocyte hypertrophy,
on channel alterations, inflammatory reactions, and so on.
lthough no pharmacological treatment is currently available to
emove the amyloid deposits, much research is being carried out
n this field (5).
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eply
e thank Dr. Leone and colleagues for their interest in our
ecently published article (1) and for their comments regarding
trial amyloid deposition being a potential mechanism for atrial
emodeling and atrial fibrillation (AF). They cited 2 studies in
upport of this theory. The study by Röcken et al. (2) found that
0 of 245 patients (16.3%) who underwent cardiac surgery had
myloid in the right atrial appendages, and of this group of 40, 14
35%) had AF. The study by Dr. Leone and colleagues consisted
f 72 patients with AF undergoing valvular surgery; 33 (46%) had
vidence of atrial amyloid, whereas only 6 of 52 (12%) patients in
inus rhythm with heart failure (serving as control subjects) had
trial amyloid (3). Both of these cross-sectional studies suggested
link between atrial amyloid and AF.
In contrast, Steiner and Hajkova (4) autopsied 100 hearts and
xamined the relationship between amyloid deposition and AF.
heir study did not show a statistical difference in either preva-
ence or severity of atrial amyloid between patients who had AF
nd those who did not.
The data from all 3 series are interesting and valuable, but
imited by: 1) their cross-sectional nature and, therefore, difficulty
ith interpretation of cause and effect; 2) the relatively small study
opulations; and 3) the fact that isolated atrial amyloid is exceed-
ngly common in older people and nearly universal in advanced
ges (86% in ages 81 to 90 years) (5). The aggregate data could
either prove nor refute the theory of amyloid as an important
ubstrate for atrial remodeling and AF development.
Furthermore, it is peculiar to note that the prevalence of AF in
myloid patients has not yet been shown to be of an inordinately
igh magnitude. One would surmise that if atrial amyloid is a
otent AF substrate, patients with cardiac amyloid should have a
1ery high prevalence of AF, especially as they almost invariably
ave large atria, and many also have restrictive diastolic physiology.
arlier publications on cardiac amyloid patients have not provided
dequate data regarding AF prevalence, because they either were
ery small series (6–10) or did not specifically evaluate the
revalence of AF (11–14). Our group has begun to review our own
myloid series regarding the prevalence/incidence of AF, and the
ata will be reported in the near future.
Indeed, the clinical impact of isolated atrial amyloid is uncer-
ain. The relationship of atrial amyloid to age and its role in left
trial remodeling and AF remain intriguing and warrant further
nvestigations.
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